Tatiana Georgiesh1,2, Kjetil Boye2,3, Bodil Bjerkehagen1,4. 1. Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway. 2. Department of Tumour Biology, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway. 3. Department of Oncology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway. 4. Institute of Clinical Medicine and Institute of Oral Biology, University of Oslo, Oslo, Norway.
Abstract
AIMS: Solitary fibrous tumours (SFTs) are rare mesenchymal neoplasms with recurrence rates of 10-30%. Current risk stratification systems for extrameningeal SFTs are based on cohorts with limited follow-up and are not suitable for prediction of late recurrences. In this study we aimed to develop a prognostic model accounting for both early and late recurrences using a relatively large patient cohort with long-term follow-up. METHODS AND RESULTS: Clinicopathological factors were analysed in a cohort of 100 extrameningeal, STAT6-positive SFTs. Median follow-up for overall survival (OS) and recurrence-free interval (RFi) were 121 and 84 months, respectively. Disease relapse occurred in 31% of patients and median time to recurrence was 63 months. In univariate analysis mitotic count, necrosis, male gender and presence of severe atypia and pleomorphism were associated with inferior RFi. Mitotic count, necrosis and male gender were independent predictors of recurrence in multivariate analysis. Previously published risk models were also statistically associated with RFi in our cohort, but failed to reliably identify low-risk patients due to poor prediction of late recurrences. A novel risk score based on mitotic count, necrosis and gender was able to stratify patients into low-, intermediate- and high-risk groups for both early and late recurrences. CONCLUSIONS: In this cohort of patients with extrameningeal SFT and long-term follow-up mitotic count, necrosis and gender were independent prognostic markers of recurrence. We propose a novel risk score based on these factors and accounting for late recurrences, which should be validated in external cohorts with sufficient follow-up time.
AIMS: Solitary fibrous tumours (SFTs) are rare mesenchymal neoplasms with recurrence rates of 10-30%. Current risk stratification systems for extrameningeal SFTs are based on cohorts with limited follow-up and are not suitable for prediction of late recurrences. In this study we aimed to develop a prognostic model accounting for both early and late recurrences using a relatively large patient cohort with long-term follow-up. METHODS AND RESULTS: Clinicopathological factors were analysed in a cohort of 100 extrameningeal, STAT6-positive SFTs. Median follow-up for overall survival (OS) and recurrence-free interval (RFi) were 121 and 84 months, respectively. Disease relapse occurred in 31% of patients and median time to recurrence was 63 months. In univariate analysis mitotic count, necrosis, male gender and presence of severe atypia and pleomorphism were associated with inferior RFi. Mitotic count, necrosis and male gender were independent predictors of recurrence in multivariate analysis. Previously published risk models were also statistically associated with RFi in our cohort, but failed to reliably identify low-risk patients due to poor prediction of late recurrences. A novel risk score based on mitotic count, necrosis and gender was able to stratify patients into low-, intermediate- and high-risk groups for both early and late recurrences. CONCLUSIONS: In this cohort of patients with extrameningeal SFT and long-term follow-up mitotic count, necrosis and gender were independent prognostic markers of recurrence. We propose a novel risk score based on these factors and accounting for late recurrences, which should be validated in external cohorts with sufficient follow-up time.
Authors: Tatiana Georgiesh; Ninna Aggerholm-Pedersen; Patrick Schöffski; Yifan Zhang; Andrea Napolitano; Judith V M G Bovée; Åse Hjelle; Gordon Tang; Mateusz Spalek; Margherita Nannini; David Swanson; Thomas Baad-Hansen; Raf Sciot; Asle C Hesla; Paul Huang; Desiree Dorleijn; Hans Kristian Haugland; Maribel Lacambra; Jacek Skoczylas; Maria A Pantaleo; Rick L Haas; Leonardo A Meza-Zepeda; Florian Haller; Anna M Czarnecka; Herbert Loong; Nina L Jebsen; Michiel van de Sande; Robin L Jones; Felix Haglund; Iris Timmermans; Akmal Safwat; Bodil Bjerkehagen; Kjetil Boye Journal: Br J Cancer Date: 2022-08-27 Impact factor: 9.075
Authors: Hye Rhyn Chung; Kenric Tam; Albert Y Han; Farres Obeidin; Manando Nakasaki; Dinesh K Chhetri; Maie A St John; Ashley E Kita Journal: OTO Open Date: 2022-07-12